Cover Image
市場調查報告書

特發性肺纖維化:全球臨床實驗趨勢

Idiopathic Pulmonary Fibrosis Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 361741
出版日期 內容資訊 英文 226 Pages
訂單完成後即時交付
價格
Back to Top
特發性肺纖維化:全球臨床實驗趨勢 Idiopathic Pulmonary Fibrosis Global Clinical Trials Review, H2, 2017
出版日期: 2017年10月31日 內容資訊: 英文 226 Pages
簡介

本報告提供全球特發性肺纖維化治療藥臨床實驗趨勢的相關調查,提供您已開發國家及新興國家市場上臨床實驗數量,各階段及各進展狀況臨床實驗數量,參與治療藥臨床實驗之主要企業,有潛力的藥劑等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量
    • 中南美主要5國的臨床實驗數量

G7各國臨床實驗數量:呼吸系統疾病治療藥臨床實驗上特發性肺纖維化的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:呼吸系統疾病治療藥臨床實驗上特發性肺纖維化的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

特發性肺纖維化治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4644CTIDB

GlobalData's clinical trial report, "Idiopathic Pulmonary Fibrosis Global Clinical Trials Review, H2, 2017" provides an overview of Idiopathic Pulmonary Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Pulmonary Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials 30
  • Prominent Drugs 32
  • Latest Clinical Trials News on Idiopathic Pulmonary Fibrosis 33
  • Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21 33
  • Sep 21, 2017: Patara Pharmas Phase 2 Study Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Mediciney Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Medicine 33
  • Sep 19, 2017: AdAlta announces additional, positive safety data of AD-114 in non-human primates 33
  • Sep 13, 2017: Results of a six-month study combining Roche's Esbriet with nintedanib in patients with IPF presented at ERS 34
  • Sep 13, 2017: Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society International Congress 2017 34
  • Sep 11, 2017: Safety and efficacy results from the INJOURNEYTM trial investigating OFEV (nintedanib) with add-on pirfenidone provide new data to support nintedanib's key role in IPF 35
  • Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials 36
  • Sep 05, 2017: FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017 36
  • Aug 22, 2017: PharmAkea Announces Successful Completion of a Phase 1 Trial in Healthy Subjects For Its Novel LOXL2 Inhibitor, PAT-1251 37
  • Aug 17, 2017: Results from Extension Study with C21 Show Safety, Tolerability and Indicate Effects on lipid Metabolism 37
  • Aug 11, 2017: Kadmon to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017 37
  • Aug 09, 2017: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial 37
  • Aug 07, 2017: FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis 38
  • Jul 18, 2017: AD-114 safe in non-human primates and manufacturing progress update 38
  • Clinical Trial Profile Snapshots 40

Appendix 224

  • Abbreviations 224
  • Definitions 224
  • Research Methodology 225
  • Secondary Research 225
  • About GlobalData 226
  • Contact Us 226
  • Source 226

List of Tables

List of Tables

  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2017* 16
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2017* 19
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures

List of Figures

  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2017* 16
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2017* 19
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
  • GlobalData Methodology 225
Back to Top